KRW 1446.0
(-0.69%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 33.5 Billion KRW | -10.03% |
2022 | 37.23 Billion KRW | -32.64% |
2021 | 55.28 Billion KRW | -13.58% |
2020 | 63.97 Billion KRW | 2579.67% |
2019 | 2.38 Billion KRW | -77.01% |
2018 | 10.38 Billion KRW | 41.05% |
2017 | 7.36 Billion KRW | -20.27% |
2016 | 9.23 Billion KRW | 0.46% |
2015 | 9.19 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 33.12 Billion KRW | -1.13% |
2024 Q2 | 23.94 Billion KRW | -27.7% |
2023 Q2 | 36.96 Billion KRW | 18.76% |
2023 Q1 | 31.12 Billion KRW | -16.41% |
2023 FY | 33.5 Billion KRW | -10.03% |
2023 Q4 | 33.5 Billion KRW | -3.31% |
2023 Q3 | 34.64 Billion KRW | -6.27% |
2022 FY | 37.23 Billion KRW | -32.64% |
2022 Q4 | 37.23 Billion KRW | -6.49% |
2022 Q3 | 39.82 Billion KRW | -7.91% |
2022 Q2 | 43.24 Billion KRW | -6.88% |
2022 Q1 | 46.43 Billion KRW | -16.01% |
2021 Q2 | 75.24 Billion KRW | 85.66% |
2021 Q3 | 64.87 Billion KRW | -13.78% |
2021 FY | 55.28 Billion KRW | -13.58% |
2021 Q4 | 55.28 Billion KRW | -14.78% |
2021 Q1 | 40.53 Billion KRW | -36.65% |
2020 Q3 | 27.74 Billion KRW | 0.0% |
2020 FY | 63.97 Billion KRW | 2579.67% |
2020 Q1 | - KRW | -100.0% |
2020 Q4 | 63.97 Billion KRW | 130.58% |
2019 Q4 | 2.38 Billion KRW | 0.0% |
2019 FY | 2.38 Billion KRW | -77.01% |
2018 FY | 10.38 Billion KRW | 41.05% |
2017 FY | 7.36 Billion KRW | -20.27% |
2016 FY | 9.23 Billion KRW | 0.46% |
2015 FY | 9.19 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 320.54 Billion KRW | 89.549% |
InBody Co.,Ltd | 274.45 Billion KRW | 87.793% |
Curexo Inc. | 107.36 Billion KRW | 68.798% |
Seegene, Inc. | 1251.45 Billion KRW | 97.323% |
i-SENS, Inc. | 498.81 Billion KRW | 93.284% |
Ray Co., Ltd. | 259.55 Billion KRW | 87.092% |
Sugentech Inc. | 133.18 Billion KRW | 74.846% |
L&C Bio Co., Ltd | 262.23 Billion KRW | 87.224% |